Literature DB >> 373652

Reticulum cell sarcoma in azathioprine-treated systemic lupus erythematosus.

M E Hehir, J R Sewell, G R Hughes.   

Abstract

The development of a reticulum cell sarcoma in the lung of a patient with systemic lupus erythematosus treated with azathioprine for 18 months is described. This possible hazard of immunosuppressive therapy is discussed in relation to patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 373652      PMCID: PMC1000328          DOI: 10.1136/ard.38.1.94

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  4 in total

1.  Development of malignant cerebral lymphoma in a patient with systemic lupus erythematosus treated with immunosuppression.

Authors:  E A Lipsmeyer
Journal:  Arthritis Rheum       Date:  1972 Mar-Apr

2.  Risk of cancer in renal-transplant recipients.

Authors:  R Hoover; J F Fraumeni
Journal:  Lancet       Date:  1973-07-14       Impact factor: 79.321

3.  Azathioprine administration to NZB X NZW hybrid mice with lupus nephritis: beneficial effect complicated by development of malignant lymphomas.

Authors:  T P Casey
Journal:  N Z Med J       Date:  1973-10-10

4.  Lymphocyte and plasma cell neoplasms associated with autoimmune diseases.

Authors:  G J Goldenberg; F Paraskevas; L G Israels
Journal:  Semin Arthritis Rheum       Date:  1971-08       Impact factor: 5.532

  4 in total
  3 in total

1.  Tuberculous spondylitis: a cause for paraplegia in lupus.

Authors:  A A Drosos; S H Constantopoulos; H M Moutsopoulos
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

Review 2.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

3.  Systemic lupus erythematosus and primary cerebral lymphoma.

Authors:  A S Woolf; G Conway
Journal:  Postgrad Med J       Date:  1987-07       Impact factor: 2.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.